Advertisement
Singapore markets close in 7 hours 2 minutes

  • Straits Times Index

    3,264.54
    -28.59 (-0.87%)
     

  • Nikkei

    37,916.18
    -543.90 (-1.41%)
     

  • Hang Seng

    17,132.62
    -68.65 (-0.40%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,163.62
    -2,636.07 (-3.95%)
     

  • CMC Crypto 200

    1,391.60
    -32.50 (-2.28%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,331.10
    -7.30 (-0.31%)
     

  • Crude Oil

    82.62
    -0.19 (-0.23%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,572.42
    +0.94 (+0.06%)
     

  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     

  • PSE Index

    6,579.19
    +6.44 (+0.10%)
     

Understanding Sarepta Therapeutics’ Operational Performance

Kenneth Smith
Updated
Understanding Sarepta Therapeutics’ Operational Performance

Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.

Continue reading